Skip to main content

Advertisement

SpringerLink
Log in

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

LIFE (non-small cell Lung cancer management In patients progressing after First-linE of treatment in the metastatic setting) is a multicentre Italian observational study, including a cross-sectional and a longitudinal phase, with the aim of describing the therapeutic approach in clinical practice for advanced non-small cell lung cancer (NSCLC) patients, progressing after first-line treatment.

Methods

In this paper, the cross-sectional phase is outlined, with the primary endpoint of describing the proportion of patients receiving second-line treatment among those progressed during or after first-line treatment according to clinical practice.

Results

From July 2011 to January 2012, 603 patients were enrolled and 541 (90 %) were evaluable. A total of 464 (86 %) patients received a second-line therapy outside clinical trials. Chemotherapy and targeted therapies were administered to 65 and 34 % of patients, respectively (1 % both). No tissue collection was required within the observational trial, and biomarkers analysis was performed at diagnosis or later in 314 patients (58 %). In details, activating epidermal growth factor receptor mutations were detected in 21 % of 311 evaluable patients, Kirsten rat sarcoma 2 viral oncogene homolog mutation in 22 % of the 77 evaluable patients and anaplastic lymphoma kinase translocations analysis was performed in 74 patients and resulted positive in 23 % of cases. These high proportions were probably due to enriched patient population tested.

Conclusions

These results showed a pattern of care for NSCLC second-line therapy which reflects international guidelines recommendations and current expected clinical practice. Interestingly, biomarkers analyses were performed in a higher percentage than expected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2011) 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825–3831

    Article  PubMed  PubMed Central  Google Scholar 

  • Bischoff HG, van den Borne B, Pimentel FL, Arellano J, Langer F, Leschinger MI, Thatcher N (2010) Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). Curr Med Res Opin 26:1461–1470

    Article  PubMed  CAS  Google Scholar 

  • de Marinis F, Rossi A, Di Maio M, Ricciardi S, Gridelli C (2011) Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 73:1–10

    Article  PubMed  Google Scholar 

  • Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836–1843

    Article  PubMed  Google Scholar 

  • Dixon WJ, Massey FJ (1983) Introduction to statistical analysis, 4th edn. McGraw-Hill, New York, pp 105–107

    Google Scholar 

  • Felip E, Gridelli C, Baas P, Rosell R, Stahel R (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 22:1507–1519

    Article  PubMed  CAS  Google Scholar 

  • Ferté C, Besse B, Dansin E, Parent F, Buisine MP, Copin MC, Penel N, Soria JC (2010) Durable responses to erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Ann Oncol 21:1385–1387

    Article  PubMed  Google Scholar 

  • Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354–2362

    PubMed  CAS  Google Scholar 

  • Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK (2010) First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5:260–274

    Article  PubMed  Google Scholar 

  • Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539–4544

    Article  PubMed  Google Scholar 

  • Gridelli C, Ardizzoni A, Barni S, Crinò L, Caprioli A, Piazza E, Lorusso V, Barbera S, Zilembo N, Gebbia V, Adamo V, Pela R, Marangolo M, Morena R, Filippelli G, Buscarino C, Alabiso O, Maione P, Venturino P, de Marinis F (2011) Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study. Lung Cancer 74:462–468

    Article  PubMed  Google Scholar 

  • Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F (2012) First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: The TORCH randomized trial. J Clin Oncol 30:3002–3011

    Article  PubMed  CAS  Google Scholar 

  • Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

    Article  PubMed  CAS  Google Scholar 

  • Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972

    Article  PubMed  CAS  Google Scholar 

  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  PubMed  CAS  Google Scholar 

  • Moro-Sibilot D, Vergnenegre A, Smit EF, Toy E, Parente B, Schmitz S, Kraaij K, Visseren-Grul C, Soldatenkova V, Arellano J, Leteneux C (2010) Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Curr Med Res Opin 26:2661–2672

    Article  PubMed  CAS  Google Scholar 

  • Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS (2006) Epidermal growth factor receptor (EGFR) signalling in cancer. Gene 366:2–16

    Article  PubMed  CAS  Google Scholar 

  • Pfizer (2012) Pfizer announces positive results from phase 3 study PROFILE 1007 evaluating XALKORI® (crizotinib) in previously treated patients with ALK-positive advanced non-small cell lung cancer. Pfizer. http://www.pfizer.com/news/press_releases/pfizer_press_release.jsp?guid=20120619005851en&source=RSS_2011&page=1. Accessed 30 July 2012

  • Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA (2010) Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 28:4769–4777

    Article  PubMed  CAS  Google Scholar 

  • Rossi A, Galetta D (2012) Biomarkers for the targeted therapies of non-small cell lung cancer. Curr Biomark Find 2:7–17

    Article  CAS  Google Scholar 

  • Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103

    PubMed  CAS  Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  PubMed  CAS  Google Scholar 

  • Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566

    Article  PubMed  CAS  Google Scholar 

  • Vergnenegre A, Smit EF, Toy E, Parente B, Schmitz S, Kraaij K, Soldatenkova V, Visseren-Grul C, Zanotti G, Taipale K, Moro-Sibilot D (2012) Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study. Curr Med Res Opin 28:1–10

    Article  Google Scholar 

Download references

Acknowledgments

Study sponsored by Boehringer Ingelheim. Scientific and technical coordination by Medidata. A special thanks goes to Carmine Ferrara from A.O.R.N. San Giuseppe Moscati (Avellino) and to Ester Del Signore from AO San Camillo Forlanini (Rome) for scientific and technical support.

Conflict of interest

The authors declare to have full control of all primary data, and they agree to allow the journal to review their data if requested. Authors declare the following conflict of interest: Gridelli Cesare, Grossi Francesco had received advisory/speaker honoraria and/or research funding from Boehringer Ingelheim Italy. de Marinis Filippo has received advisory/speaker honoraria and/or research funding from Boehringer Ingelheim Italy and Roche. Ardizzoni Andrea has received advisory/speaker honoraria and/or research funding from Boehringer Ingelheim Italy, Glaxo Smith-Kline, Eli Lilly, Pfizer, Pierre Fabre, Daiicki-Sankyo. Novello Silvia, Cortinovis Diego had received advisory/speaker honoraria and/or research funding from Boehringer Ingelheim Italy, Roche, Astra Zeneca, Eli Lilly. The following authors declare no conflict of interest instead: Cappuzzo Federico, Favaretto Adolfo, Bettini Anna, Siena Salvatore, Caprioli Alberto, Iurlaro Monica, Fontanini Gabriella, Santo Antonio, Lorusso Vito, Galetta Domenico.

Ethical standard

This study was approved by appropriate ethics committees and was therefore performed in accordance with ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

All persons gave their informed consent prior to their inclusion in the study.

Author information

Authors and Affiliations

  1. A.O.R.N. San Giuseppe Moscati, Contrada Amoretta, 83100, Avellino, AV, Italy

    Cesare Gridelli

  2. UOC Pneumologia Oncologica, A.O. San Camillo Forlanini, Circonvallazione Gianicolense 87, 00151, Rome, RM, Italy

    Filippo de Marinis

  3. Thoracic Oncology Division, European Institute of Oncology (IEO), Via Ripamonti 435, 20141, Milan, MI, Italy

    Filippo de Marinis

  4. Azienda Ospedaliera di Parma, Via Gramsci 14, 43126, Parma, PR, Italy

    Andrea Ardizzoni

  5. Università di Torino, A.O.U. San Luigi Gonzaga, Regione Gonzole 10, 10043, Orbassano, TO, Italy

    Silvia Novello

  6. Azienda Ospedaliero Universitaria Pisana, Via Roma, 67, 56126, Pisa, PI, Italy

    Gabriella Fontanini

  7. Ospedale di Livorno, Via Alfieri 36, 57124, Livorno, LI, Italy

    Federico Cappuzzo

  8. IRCCS A.O.U. San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Largo Benzi 10, 16132, Genoa, GE, Italy

    Francesco Grossi

  9. Gruppo Interdisciplinare Veronese Oncologia Polmonare (GIVOP), AOUI-Verona, Piazzale Stefani 1, 37126, Verona, VR, Italy

    Antonio Santo

  10. UO Oncologia Medica, Ospedale San Gerardo, Via Pergolesi 33, 20900, Monza, MB, Italy

    Diego Cortinovis

  11. UOC Oncologia Medica 2, Istituto Oncologico Veneto IOV, Via Gattamelata 64, 35128, Padua, PD, Italy

    Adolfo Favaretto

  12. Oncologia Medica Pad. Oncologico, Ospedale V. Fazzi, Piazza Muratore 1, 73100, Lecce, LE, Italy

    Vito Lorusso

  13. Oncologia Medica, IRCCS Giovanni Paolo II Ospedale Oncologico, Via Flacco 65, 70124, Bari, BA, Italy

    Domenico Galetta

  14. S.C. Oncologia Falck, Ospedale Niguarda Ca’ Granda, Piazza Ospedale Maggiore 3, 20162, Milan, MI, Italy

    Salvatore Siena

  15. UO Oncologia Medica, A.O. Papa Giovanni XXIII, Piazza OMS 1, 24127, Bergamo, BG, Italy

    Anna Bettini

  16. Boehringer Ingelheim S.p.A., Via Lorenzini 8, 20139, Milan, MI, Italy

    Monica Iurlaro

  17. Pneumologia, A.O. Spedali Civili di Brescia, Piazzale Spedali Civili 1, 25123, Brescia, BS, Italy

    Alberto Caprioli

Authors
  1. Cesare Gridelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filippo de Marinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Ardizzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Novello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gabriella Fontanini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Federico Cappuzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesco Grossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonio Santo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Diego Cortinovis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Adolfo Favaretto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Vito Lorusso
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Domenico Galetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Salvatore Siena
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Anna Bettini
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Monica Iurlaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Alberto Caprioli
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of LIFE study team

Corresponding author

Correspondence to Cesare Gridelli.

Appendix: The LIFE study team

Appendix: The LIFE study team

Filippo

De Marinis

AO San Camillo Forlanini

Roma

Cesare

Gridelli

A.O.R.N. San Giuseppe Moscati

Avellino

Antonio

Santo

Gruppo Interdisciplinare Veronese Oncologia Polmonare, AOUI

Verona

Diego

Cortinovis

Ospedale San Gerardo

Monza

Adolfo

Favaretto

Istituto Oncologico Veneto—IOV

Padova

Vito

Lorusso

Ospedale V. Fazzi

Lecce

Annamaria

Catino

IRCCS “Giovanni Paolo II” Ospedale Oncologico

Bari

Salvatore

Siena

Ospedale Niguarda Ca’ Granda

Milano

Anna

Bettini

Az. Osp. Ospedali Riuniti

Bergamo

Alberto

Caprioli

Spedali Civili di Brescia

Brescia

Andrea

Ardizzoni

Azienda Ospedaliera di Parma

Parma

Silvia

Novello

A.O.U. San Luigi Gonzaga

Orbassano

Paolo

Pedrazzoli

IRCCS Policlinico San Matteo

Pavia

Oscar

Alabiso

A.O.U. Maggiore della Carità

Novara

Domenico

Bilancia

Azienda Ospedaliera San Carlo

Potenza

Saverio

Cinieri

P.O. Antonio Perrino

Brindisi

Michele

Milella

Istituto Regina Elena

Roma

Giacomo

Cartenì

AORN “A. Cardarelli”

Napoli

Alfredo

Falcone

Azienda Ospedaliero Universitaria Pisana

Pisa

Gianpiero

Fasola

Azienda Ospedaliera Universitaria di Udine

Udine

Francesco

Ferraù

Ospedale San Vincenzo

Taormina

Antonio

Contu

Ospedale Civile SS. Annunziata

Sassari

Dario

Giuffrida

Istituto Oncologico del Mediterraneo

Viagrande

Alfonso

Illiano

A.O.R.N. Monaldi

Napoli

Alberto

Ravaioli

Ospedale degli Infermi

Rimini

Alberto

Zaniboni

Fondazione Poliambulanza

Brescia

Sandro

Barni

Ospedale Treviglio-Caravaggio

Treviglio

Giorgio

Cruciani

Ospedale di Lugo Umberto I

Lugo

Flavia

Longo

Policlinico Umberto I

Roma

Federico

Cappuzzo

Ospedale di Livorno

Livorno

Efisio

Defraia

Ospedale Oncologico Businico

Cagliari

Francesco

Di Costanzo

A.O.U. Ospedale Careggi

Firenze

Teresa

Gamucci

Ospedale S.S. Trinità

Sora

Dino

Amadori

IRST di Meldola

Meldola

Michele

Caruso

Humanitas Centro Catanese di Oncologia

Catania

Mario

Clerico

Ospedale degli Infermi

Biella

Francesco

Grossi

IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Istituto Nazionale per la Ricerca sul Cancro

Genova

Graziella

Pinotti

Ospedale di Circolo e Fondazione Macchi

Varese

Stefano

Iacobelli

Ospedale SS Annunziata

Chieti Scalo

Daniele

Pozzessere

Ospedale Misericordia e Dolce AUSL4 di Prato

Prato

Roberto

Bianco

A.O.U. Federico II

Napoli

Evaristo

Maiello

Casa Sollievo della Sofferenza

San Giovanni Rotondo

Paolo

Marchetti

Azienda Ospedaliera Sant’Andrea

Roma

Rodolfo

Passalacqua

Azienda Istituti Ospitalieri

Cremona

Lorenzo

Pavesi

Fondazione S. Maugeri IRCCS

Pavia

Stefano

Tamberi

Ospedale degli Infermi

Faenza

Giampaolo

Tortora

Policlinico G.B. Rossi di Borgo Roma

Verona

Massimo

Aglietta

IRCC Istituto per la Ricerca e la Cura del Cancro

Candiolo

Alba

Brandes

Ospedale Bellaria

Bologna

Libero

Ciuffreda

Azienda Ospedaliera Città della Salute e della Scienza

Torino

Bruno

Daniele

Ospedale G. Rummo

Benevento

Claudio

Demichelis

Ospedale Unificato d’Imperia

Imperia

Sante

Romito

Az. Osp. Univ. Ospedali Riuniti

Foggia

Fausto

Barbieri

Az. Osp. Univ. Policlinico

Modena

Lucio

Crinò

Azienda Ospedaliera Perugia

Perugia

Monica

Giordano

Az. Osp. Sant’ Anna

San Fermo della Battaglia

Sergio

Bracarda

Ospedale San Donato

Arezzo

Nicola

Marzano

Ospedale San Paolo

Bari

Marco

Merlano

A.S.O. S. Croce e Carle

Cuneo

Gianmauro

Numico

Ospedale Regionale U.Parini

Aosta

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gridelli, C., de Marinis, F., Ardizzoni, A. et al. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. J Cancer Res Clin Oncol 140, 1783–1793 (2014). https://doi.org/10.1007/s00432-014-1715-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1715-2

Keywords

Search

Navigation